Embryonic Stem Cells News and Research

RSS

BD, Walter and Eliza Hall Institute collaborate to commercialize antibodies

The Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, has entered a collaboration with New Jersey based medical technology company BD to evaluate and potentially develop for research and diagnostic use some of the institute's reagents.

19 Oct 2010

Researchers report breakthrough studies in liver cell transplantation

Two research teams from the Okayama University Graduate School of Medicine (Okayama, Japan) have reported breakthrough studies in liver cell transplantation.

19 Oct 2010

Shrink reveals image of StemDisc450 biomedical research tool

Shrink Nanotechnologies, Inc. an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, revealed an image of its first product offering the StemDisc450, a high-yield, low cost, patent-pending cell culturing biomedical research tool.

18 Oct 2010

Emerging Healthcare anticipates results of FDA-approved human embryonic stem-cell treatment

Emerging Healthcare Solutions, Inc. eagerly anticipates the results of the first FDA-approved human embryonic stem-cell treatment on a patient with spinal cord injuries, which began this week.

15 Oct 2010

New York Stem Cell Foundation names first six NYSCF Investigators

In an expansion of its ongoing effort to promote the next generation of stem cell scientists, The New York Stem Cell Foundation (NYSCF) today named the first six NYSCF Investigators. Each of the NYSCF-Robertson and NYSCF-Helmsley Investigators will receive up to $1.5 million over the next five years to expand their own laboratories, train other scientists and foster innovative high-risk/high reward research to explore the therapeutic potential of stem cells derived from humans and model organisms.

13 Oct 2010

First Edition: October 12, 2010

Today's early morning highlights from major news organizations look at a probe of a California hospital chain, the effect that the governors' races around the country will have on the federal health law and a review of prescription purchases that shows more Americans are foregoing their medicines.

12 Oct 2010

New microchip technology to identify neuronal regenerators

Scientists have long sought the ability to regenerate nerve cells, or neurons, which could offer a new way to treat spinal-cord damage as well as neurological diseases such as Alzheimer's or Parkinson's. Many chemicals can regenerate neurons grown in Petri dishes in the lab, but it's difficult and time-consuming to identify those chemicals that work in live animals, which is critical for developing drugs for humans.

12 Oct 2010

Embryonic stem cells used in first trial for spinal cord injury

The first ever patient to receive treatment in a U.S. government approved study involving human embryonic stem cells has been injected with millions of the potentially life saving cells. He is presently being treated at the Shepherd Center in Atlanta. He was partially paralyzed following a spinal cord injury. The center specializes in treating these types of injuries.

11 Oct 2010

Geron commences GRNOPC1 hESC-based cell therapy in patients with spinal cord injury

Geron Corporation today announced the enrollment of the first patient in the company's clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1. The primary objective of this Phase I study is to assess the safety and tolerability of GRNOPC1 in patients with "complete" American Spinal Injury Association (ASIA) Impairment Scale grade A thoracic spinal cord injuries. Participants in the study must be newly injured and receive GRNOPC1 within 14 days of the injury.

11 Oct 2010

Cell Cure to receive equity investment of $7.1 million to develop stem cell-based therapies

BioTime, Inc. Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Cure will receive an equity investment of $7.1 million from BioTime, Teva Pharmaceutical Industries Ltd., and Hadasit Bio-Holdings (HBL).

11 Oct 2010

Cell Cure, Teva Pharmaceutical enter license option agreement for OpRegen product

BioTime, Inc., Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Cure and Teva Pharmaceutical Industries Ltd. have entered into an exclusive license option agreement to develop and commercialize Cell Cure's OpRegen product for the treatment of age-related macular degeneration (AMD).

11 Oct 2010

Roche´s Cellavista System useful for automated mES colony imaging: Study

A recent study depicted the use of Roche´s Cellavista System to rapidly and effectively carry out a clonal analysis of embryonic stem colony self-renewal in an end-point assay. The Cellavista System proved to be useful for automated mES colony imaging, as well as characterization of colonies as differentiated and undifferentiated based on gating of morphological and intensity criteria. Little or no interference from the feeder cell layers was seen in the analysis of the images.

8 Oct 2010

ISCO to present data on Hepatocyte-like cells at ASSLD Annual Meeting

International Stem Cell Corporation, will present data on its progress toward producing human liver cells from immune-matched patient-specific parthenogenetic stem cells at The Liver Meeting, the 61st Annual Meeting of the American Association for the Study of Liver Diseases (ASSLD), in Boston, MA from October 29 - November 2, 2010.

8 Oct 2010

GE Healthcare launches first human cellular assay product

Geron Corporation today announced that GE Healthcare has launched the first human cellular assay product for use in drug discovery and toxicity screening, developed under a license and alliance agreement between the two companies.

5 Oct 2010

Researchers identify ways to predict embryonic developmental success

Two-thirds of all human embryos fail to develop successfully. Now, in a new study, researchers at the Stanford University School of Medicine have shown that they can predict with 93 percent certainty which fertilized eggs will make it to a critical developmental milestone and which will stall and die. The findings are important to the understanding of the fundamentals of human development at the earliest stages, which have largely remained a mystery despite the attention given to human embryonic stem cell research.

4 Oct 2010

BCBC awards grant for cell therapy research in type 1 diabetes

Maike Sander, MD, associate professor of pediatrics and cellular & molecular medicine at the University of California, San Diego School of Medicine has been awarded nearly $5 million by the Beta Cell Biology Consortium (BCBC) to lead an interdisciplinary team in cell therapy research for type 1 diabetes.

4 Oct 2010

Researchers study potential of menstrual blood-derived stem cells for stroke therapy

The potential for stem cells derived from menstrual blood to benefit stroke sufferers will be jointly investigated by researchers at the University of South Florida, Cryo-Cell International, Inc., a global stem cell company based in Oldsmar, FL, and Saneron CCEL Therapeutics, Inc. a Tampa-based biotechnology company.

1 Oct 2010

McLean Researchers receive award to create first clinic-ready human induced iPS cells

Belmont, MA-Researchers at Harvard Affiliated McLean Hospital have been awarded a $1.9 million National Institutes of Health Director's Opportunity Award to continue their research into creating human induced pluripotent (iPS) stem cells using a method aimed at eliminating the risk of cancer and other problems associated with other options such as genome-integrating viral methods.

30 Sep 2010

Federal appeals court rules NIH can continue to fund stem cell research

The Wall Street Journal: "A federal appeals court said Tuesday the Obama administration can continue to fund embryonic stem-cell research, reversing for the time being a trial judge's injunction barring the funding. The one-page order by a three-judge panel of the U.S Court of Appeals for the District of Columbia Circuit said the administration met the legal standard for a stay of the injunction, but didn't discuss the case in detail.

30 Sep 2010

First Edition: September 29, 2010

In today's headlines, reports about the continuing politics surrounding the health overhaul, as both parties vie for the loyalty of older voters and First Lady Michelle Obama steps up efforts to promote the new law.

29 Sep 2010